In conclusion, ablation of expression Rora was shown to promote Ph+ B-ALL progression using BCR/ABL1-induced B-ALL mouse models; whereas activation of Rora with a specific agonist (CS) inhibited Ph+ B-ALL progression. The gene discussed is BCR; the disease is acute lymphoblastic leukemia.